Objectives: Women of reproductive age commonly use hormonal contraceptives, the vocal effects of which have been studied. Otolaryngologists should be aware of this relationship to make recommendations on hormonal contraception as it relates to each patient's voice requirements.
Methods/design: A comprehensive literature review of PubMed was completed. The terms "contraception," "vocal folds," "vocal cords," and "voice" were searched in various combinations. Articles from 1971 to 2015 that addressed the effects of contraception on the vocal folds were included.
Results: In total, 24 articles were available for review. Historically, contraception was believed to affect the voice negatively. However, more recent studies using low-dose oral contraceptive pills (OCPs) show that they stabilize the voice. However, stabilization generally occurs only during sustained vowel production; connected speech appears unaffected. Therefore, singers may be the only population that experiences clinically increased vocal stability as a result of taking hormonal contraceptives. Only combined OCPs have been studied; other forms of hormonal contraception have not been evaluated for effects on the voice. Significant variability exists between studies in the physical attributes of patients and parameters tested.
Conclusions: Hormonal contraception likely has no clinically perceptible effects on the speaking voice. Singers may experience increased vocal stability with low-dose, combined OCP use. Other available forms of contraception have not been studied. Greater consistency in methodology is needed in future research, and other forms of hormonal contraception require study.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jvoice.2015.08.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
BARRIERS TO PRESCRIPTION OF HORMONAL CONTRACEPTION AND HORMONE REPLACEMENT THERAPY IN GYNECOLOGICAL CANCER SURVIVORS: RESULTS OF A SURVEY AND LITERATURE REVIEW.
J Gynecol Obstet Hum Reprod
December 2024
Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal; Portuguese Gynecologic Oncology Section of the Portuguese Society of Gynecology. Electronic address:
Background: The incidence of gynecological cancers in premenopausal women is increasing, highlighting issues related to Hormonal Contraception (HC) and Hormone Replacement Therapy (HRT). However, the presence of hormonal receptors in many gynecological cancers complicates HC and HRT prescriptions.
Objective: To identify barriers experienced by gynecologists in prescribing HC and HRT to gynecological cancer survivors, with a secondary objective of conducting a literature review on the safety of these prescriptions.
The role of short luteal phases on cycle regularity during the perimenopausal transition.
Menopause
December 2024
From the University of Aarhus, Institute for Clinical Medicine, Aarhus, Denmark.
Objective: The aim of the study was to explore the correlation between short luteal phases and cycle irregularity in perimenopausal women.
Methods: In this feasibility pilot study, daily salivary-progesterone measurements from presumed perimenopausal women have been analyzed using the inne minilab-an at-home system for ovulation and cycle tracking. Data were collected between 2020 to August 2022 from 29 women from Germany and Austria from users over the age of 42 years.
Health care professionals' views on a new postpartum contraception audiovisual animation: a survey.
BMJ Sex Reprod Health
December 2024
Sexual and Reproductive Health, NHS Lothian, Edinburgh, UK.
Background: The postpartum period is a high-risk time for unintended pregnancy. We developed a 2-minute audiovisual animation on postpartum contraception (PPC) including the return of fertility after birth for patients. The aim of our study was to determine the views of healthcare professionals (HCPs) involved in pregnancy care on the animation and to identify facilitators and barriers to its implementation into routine pregnancy care pathways.
View Article and Find Full Text PDFImpact of progestin type on the risk of drug interactions between combined oral contraceptives and psychotropic drugs: a pooled analysis of real-world data.
Contraception
December 2024
LVR-University Hospital Essen, Department of Psychiatry and Psychotherapy, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany; Center for Translational Neuro- and Behavioral Sciences, University of Duisburg-Essen, Essen, Germany; Bielefeld University, Medical School and University Medical Center OWL, Protestant Hospital of the Bethel Foundation, Department of Psychiatry and Psychotherapy.
Objective: To assess the risk of contraceptive failure and adverse events (AEs) associated with the type of progestin when co-administered with psychotropic drugs within a routine clinical practice setting.
Study Design: A pooled analysis of four large, prospective, multinational cohort studies including women with a new prescription of combined oral contraceptives (COCs) and concomitant psychotropic drug use from 13 European countries and the United States. We determined the frequency of contraceptive failures and AEs within six months after COC initiation by progestin type.
Non-daily contraception: Reinforcing the choice of users and addressing unmet needs of reproductive health.
Acta Obstet Gynecol Scand
December 2024
Department of Women's and Children's Health, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Despite great societal efforts promoting female autonomy, Sweden still faces unmet contraceptive needs, with abortion rates being the highest in the Nordic countries. In this commentary, we discuss using non-daily contraception options to combat these unmet needs. Non-daily methods include transdermal (i.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!